Search hospitals > Illinois > Macomb
Illinois CancerCare-Macomb
Claim this profileMacomb, Illinois 61455
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Non-Small Cell Lung Cancer
401 reported clinical trials
14 medical researchers
Summary
Illinois CancerCare-Macomb is a medical facility located in Macomb, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Illinois CancerCare-Macomb is involved with conducting 401 clinical trials across 476 conditions. There are 14 research doctors associated with this hospital, such as Bryan A. Faller, Ammar Sukari, Anteneh A. Tesfaye, and Anthony F. Shields.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Bryan A. FallerCrossroads Cancer Center2 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
223 reported clinical trials
289 drugs studied
Ammar SukariWayne State University/Karmanos Cancer Institute1 year of reported clinical research
Expert in Squamous Cell Carcinoma
Expert in Cancer
27 reported clinical trials
44 drugs studied
Anteneh A. TesfayeWayne State University/Karmanos Cancer Institute4 years of reported clinical research
Studies Colorectal Cancer
Studies Tumors
18 reported clinical trials
37 drugs studied
Anthony F. ShieldsBarbara Ann Karmanos Cancer Institute4 years of reported clinical research
Studies Solid Tumors
Studies Tumors
20 reported clinical trials
62 drugs studied
Clinical Trials running at Illinois CancerCare-Macomb
Breast Cancer
Prostate Cancer
Cancer
Gastric Cancer
Lung Cancer
Bladder Cancer
Gastroesophageal Junction Adenocarcinoma
Non-Small Cell Lung Cancer
Esophageal Cancer
Esophageal Adenocarcinoma
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Illinois CancerCare-Macomb?
Illinois CancerCare-Macomb is a medical facility located in Macomb, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Illinois CancerCare-Macomb is involved with conducting 401 clinical trials across 476 conditions. There are 14 research doctors associated with this hospital, such as Bryan A. Faller, Ammar Sukari, Anteneh A. Tesfaye, and Anthony F. Shields.
Where is Illinois CancerCare-Macomb located?
Illinois CancerCare-Macomb is located at McLaren Macomb hospital, 1000 Harrington Ave, Mount Clemens, MI 48043. Henry Ford Cancer - Macomb Hospital can be found at 15855 19 Mile Road, Clinton Township, MI 48038.
Who should I call to ask about financial aid or insurance network?
**Illinois CancerCare-Macomb Hospital Financial Assistance and Insurance Contact Information:**
**Financial Assistance:**
- Credit Office: (309) 836-1528
**Insurance:**
- Financial Services (Patient Billing): (309) 836-1524
For further financial support, CancerCare provides limited assistance for cancer-related costs (contact at 800-813-HOPE (4673)), and the Illinois Department of Healthcare and Family Services offers Medicaid and medical assistance programs for qualifying individuals.
What insurance does Illinois CancerCare-Macomb accept?
Illinois CancerCare-Macomb accepts a wide range of insurance plans such as Aetna Choice POS II, Aetna HMO, Aetna Managed Choice POS Open Access, Aetna Signature Administrators PPO, BCBS Blue Card PPO, and Medicare. Patients are advised to verify physician participation in their insurance plan and confirm if pre-certification is required. Co-payments are due at the time of visit, and patients are responsible for all charges incurred.
What awards or recognition has Illinois CancerCare-Macomb received?
Illinois CancerCare, with its Macomb location, stands out as a leading participant in clinical research, acknowledged by the Alliance for Clinical Trials in Oncology for its high enrollment rates. It has earned recognition from the Quality Oncology Practice Initiative (QOPI®) Certification Program, highlighting its commitment to the highest standards of outpatient hematology-oncology care. As central Illinois' largest network of cancer care specialists, Illinois CancerCare conducts around 100 open clinical cancer research trials at any given time.